| Literature DB >> 33718942 |
Ana Sofia Da Silva1, Georgina Baines1, George Araklitis1, Dudley Robinson1, Linda Cardozo1.
Abstract
The genitourinary syndrome of menopause (GSM) is the accepted term used to describe the broad spectrum of genitourinary tract symptoms and signs caused by the loss of endogenous sex steroids that occurs at the time of and after the menopause. Global improvements in healthcare have resulted in an ageing population. Today, women are spending 40% of their lives in the postmenopausal state, and with 50-70% of postmenopausal women reporting symptomatic GSM, safe and efficacious treatments are needed for this troublesome condition. This article reviews current evidence for non-pharmacological and pharmacological treatments with a focus on novel and minimally invasive procedures such as energy-based devices (CO2 laser, YAG laser), hyaluronic acid, dehydroepiandrosterone, and selective oestrogen receptor modulators. Copyright:Entities:
Keywords: CO2 laser; DHEA; Er:YAG; GSM; Genitourinary syndrome of menopause; Hyaluronic acid; Intrarosa; Laser; Lubricants; Moisturisers; Oestrogen; Orasterone; Ospemifene; Osphena; Ovestin; SERMS; Vagifem
Year: 2021 PMID: 33718942 PMCID: PMC7946389 DOI: 10.12703/r/10-25
Source DB: PubMed Journal: Fac Rev ISSN: 2732-432X